Overview

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to determine the safety, tolerability, pharmacokinetics and anti-viral activity of JTK-853 in hepatitis C virus genotype 1 infected subjects based on reduction in viral load (HCV RNA level) from baseline to end of treatment, followed by genotypic resistance monitoring for up to one year after study drug treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Akros Pharma Inc.

Treatments:

Antiviral Agents